NEW YORK, Jan. 03, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of InfuSystem Holdings, Inc. (“InfuSystem” or “the Company”) (NYSE MKT:INFU) between May 12, 2015 and November 7, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. To get more information go to:
http://www.zlk.com/pslra/infusystem-holdings
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period InfuSystem made false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective internal control over financial reporting; (2) InfuSystem’s financial statements dating back to the beginning of 2015 overstated the estimated accounts receivable collections, which in turn overstated revenues and pre-tax income by a corresponding amount; (3) InfuSystem’s financial statements dating back to the beginning of 2015 could no longer be relied upon; and (4) as a result of the foregoing, InfuSystem’s financial statements were materially false and misleading at all relevant times.
If you suffered a loss in InfuSystem you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 



